Delineation of prognostic biomarkers in prostate cancer by Dhanasekaran, Saravana M. et al.
letters to nature
822 NATURE | VOL 412 | 23 AUGUST 2001 | www.nature.com
Received 29 March; accepted 25 June 2001.
1. Hyman, L. H. The Invertebrates Vol. 4 (McGraw-Hill, New York, 1955).
2. Millott, N. The photosensitivity of echinoids. Adv. Mar. Biol. 13, 1±52 (1975).
3. Yoshida, M., Takasu, N. & Tamotsu, S. in Photoreception and Vision in Invertebrates; (ed. Ali, M. A.)
743±771 (Plenum, New York, 1984).
4. Lowenstam, H. A. & Weiner, S. On Biomineralization 123±134 (Oxford Univ. Press, Oxford, 1989).
5. Wainwright, S. A., Biggs, W. D., Currey, J. D. & Gosline, J. M. Mechanical Design in Organisms (John
Wiley, New York, 1976).
6. Hendler, G. & Byrne, M. Fine structure of the dorsal arm plate of Ophiocoma wendti (Echinodermata,
Ophiuroidea). Zoomorphology 107, 261±272 (1987).
7. Hendler, G. Brittlestar color-change and phototaxis (Echinodermata: Ophiuroidea: Ophiocomidae).
Mar. Ecol. 5, 379±401 (1984).
8. Cowles, R. P. Stimuli produced by light and by contact with solid walls as factors in the behavior of
ophiuroids. J. Exp. Zool. 9, 387±416 (1910).
9. Donnay, G. & Pawson, D. L. X-ray diffraction studies of echinoderm plates. Science 166, 1147±1150
(1969).
10. Ameye, L., Hermann, R., Wilt, F. & Dubois, P. Ultrastructural localization of proteins involved in sea
urchin biomineralization. J. Histochem. Cytochem. 47, 1189±1200 (1999).
11. Clarkson, E. N. K. & Levi-Setti, R. Trilobite eyes and the optics of Des Cartes and Huygens. Nature 254,
663±667 (1975).
12. Gal, J., Horvath, G., Clarkson, E. N. K. & Haiman, O. Image formation by bifocal lenses in a trilobite
eye? Vision Res. 40, 843±853 (2000).
13. Towe, K. M. Trilobite eyes: calci®ed lenses in vivo. Science 179, 1007±1010 (1973).
14. DoÈderlein, L. Ueber `KrystallkoÈrper' bei Seesternen. Denkschr. Med. Nat. Ges. Jena 8, 491±494 (1898).
15. Smith, A. B. in Special Papers in Palaeontology 25, 1±81 (Palaeontology Association, London, 1980).
16. Xia, Y. N. & Whitesides, G. M. Soft lithography. Annu. Rev. Mater. Sci. 28, 153±184 (1998).
17. Aizenberg, J., Rogers, J. A., Paul, K. E. & Whitesides, G. M. Imaging the irradiance distribution in the
optical near ®eld. Appl. Phys. Lett. 71, 3773±3775 (1997).
18. Flint, H. T. Geometrical Optics (Methuen, London, 1936).
19. Cobb, J. L. S. & Moore, A. Comparative studies on receptor structure in the brittlestar Ophiura
ophiura. J. Neurocytol. 15, 97±108 (1986).
20. Johnsen, S. Identi®cation and localization of a possible rhodopsin in the echinoderms Asterias forbesi
(Asteroidea) and Ophioderma brevispinum (Ophiuroidea). Biol. Bull. 193, 97±105 (1997).
21. Cobb, J. L. S. & Hendler, G. Neurophysiological characterization of the photoreceptor system in
brittlestars. Comp. Biochem. Physiol. 97A, 329±333 (1990).
22. Stubbs, T. R. in Echinoderms (ed. Lawrence, J. M.) 403±408 (Proc. Int. Echinoderms Conf., Tampa
Bay, 1982).
23. Land, M. F. in Comparative Physiology and Evolution in Invertebrates B: Invertebrate Visual Centers and
Behavior I (ed. Autrum, H.) 471±592 (Springer, Berlin, 1981).
24. Mann, S. & Ozin, G. A. Synthesis of inorganic materials with complex form. Nature 382, 313±318
(1996).
25. Belcher, A. M., Hansma, P. K., Stucky, G. D. & Morse, D. E. First steps in harnessing the potential of
biomineralization. Acta Mater. 46, 733±736 (1998).
Acknowledgements
We thank P. Wiltzius and M. Megens for helpful discussions.
Correspondence and requests for materials should be addressed to J.A.
(e-mail: jaizenberg@lucent.com).
.................................................................
Delineation of prognostic biomarkers
in prostate cancer
Saravana M. Dhanasekaran*, Terrence R. Barrette*, Debashis Ghosh²,
Rajal Shah*, Sooryanarayana Varambally*, Kotoku Kurachi³,
Kenneth J. Pienta§k¶, Mark A. Rubin*§¶# & Arul M. Chinnaiyan*§¶#
Departments of * Pathology, ² Biostatistics, ³ Human Genetics, § Urology,
k Internal Medicine, and ¶ Comprehensive Cancer Center, University of Michigan
Medical School, Ann Arbor, Michigan 48109, USA
# These authors share senior authorship
..............................................................................................................................................
Prostate cancer is the most frequently diagnosed cancer in Ameri-
can men1,2. Screening for prostate-speci®c antigen (PSA) has led
to earlier detection of prostate cancer3, but elevated serum PSA
levels may be present in non-malignant conditions such as benign
prostatic hyperlasia (BPH). Characterization of gene-expression
pro®les that molecularly distinguish prostatic neoplasms may
identify genes involved in prostate carcinogenesis, elucidate
clinical biomarkers, and lead to an improved classi®cation of
prostate cancer4±6. Using microarrays of complementary DNA, we
examined gene-expression pro®les of more than 50 normal and
neoplastic prostate specimens and three common prostate-cancer
cell lines. Signature expression pro®les of normal adjacent pros-
tate (NAP), BPH, localized prostate cancer, and metastatic, hor-
mone-refractory prostate cancer were determined. Here we
establish many associations between genes and prostate cancer.
We assessed two of these genesÐhepsin, a transmembrane serine
protease, and pim-1, a serine/threonine kinaseÐat the protein
level using tissue microarrays consisting of over 700 clinically
strati®ed prostate-cancer specimens. Expression of hepsin and
pim-1 proteins was signi®cantly correlated with measures of
clinical outcome. Thus, the integration of cDNA microarray,
high-density tissue microarray, and linked clinical and pathology
data is a powerful approach to molecular pro®ling of human
cancer.
We developed a 9,984-element (10K) human cDNA microarray
to analyse gene expression pro®les in benign and malignant prostate
tissue. As with previous cancer pro®ling studies7±10, molecular
classi®cation of prostate cancer was one of the goals of this analysis.
We used two distinct reference samples for comparative microarray
analysis: NAP tissue from patients with prostate cancer, and
prostate tissue from men without documented prostate pathology.
By making direct comparisons against normal tissue counterparts,
we took advantage of a `subtractive' effect, which emphasized genes
that consistently distinguished normal and neoplastic tissues.
Prostate tissues used in microarray analysis included 4 BPH
samples, 8 NAP samples, 1 commercial pool of normal prostate
tissue (from 19 individuals), 1 prostatitis sample, and 11 localized
and 7 metastatic prostate-cancer samples. Three cell lines from
metastatic prostate cancer (DU-145, LnCAP and PC3) were also
pro®led for gene expression. Twenty-eight additional prostate tissue
specimens were pro®led and the data included in the Supplemen-
tary Information (samples of 9 BPH, 1 NAP, 13 metastatic and 5
localized prostate cancers). Fluorescently labelled (Cy5) cDNA was
prepared from total RNA from each experimental sample. A second
distinguishable ¯uorescent dye (Cy3) was used to label the two
reference samples used in this study: a pool of NAP from four
independent patients with prostate cancer and a commercial pool of
normal prostate tissues. A direct comparison between the NAP and
commercial pools was also made and notable differences in gene
expression were readily apparent (Fig. 1 and Supplementary
Information).
In all, more than 80 cDNA microarrays were used to assess gene
expression in four clinical states of prostate-derived tissues and two
distinct reference pools of normal specimens. Figure 1 provides an
overview of the variation in gene expression across the different
tissue specimens analysed (the full data set and 28 further samples
can be seen in the Supplementary Information). A hierarchical
clustering algorithm was used to group genes and experimental
samples on the basis of similarities of gene expression over all that
were tested. Relationships between the experimental samples are
summarized as dendrograms (Fig. 1a), in which the pattern and
length of the branches re¯ect the relatedness of the samples. Benign
conditions of the prostate, such as BPH and NAP, cluster separately
from malignant prostate-cancer cell lines or tissues, regardless of the
reference pool used. Within the prostate-cancer cluster, metastatic
and clinically localized prostate cancer formed distinct subgroups.
Eisen matrix formats11 of the variation in gene expression show
clusters of coordinately expressed genes, highlighting relationships
between specimens (black bars in Fig. 1b, c). For example, clusters
B3 and C1 represent genes downregulated in both localized and
metastatic prostate cancer (Fig. 1b, c). By contrast, clusters B6 and
B4 highlight genes that are speci®cally up- or downregulated in
metastatic prostate cancer, respectively (Fig. 1b). IGFBP-5, DAN1,
FAT tumour suppressor and RAB5A are examples of genes that are
downregulated speci®cally in metastatic prostate cancer and also
have a proposed role in oncogenesis (magni®ed regions, Fig. 1b).
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Similarly, cancer-related genes that are upregulated in metastatic
prostate cancer include MTA-1 (metastasis-associated 1), MYBL2
and FLS353 (preferentially expressed in colorectal cancer).
We used several methods of gene selection to create a more
limited set of genes for future exploration. In one method (others
can be found in the Supplementary Information), we computed t-
statistics (of prostate cancer versus benign tissue) for each gene.
First, the t-values were ranked by absolute magnitude, which takes
into account the inter-sample variability in expression ratios.
Second, they were ranked by the magnitude of the numerator of
the test statistic, which is based on the biological difference in
expression ratios and designated as `effect size'. We examined a list
of the genes with the 200 largest effect sizes and 200 largest t-
values and a scatterplot of their values (see Supplementary
Information Fig. 5) to identify candidate genes. Implementing
this methodology on both reference-pool data sets yielded genes
that included HPN (hepsin), PIM1, LIM (ENIGMA), TIMP2,
HEVIN, RIG and THBS1 (thrombospondin-1), among others.
Several genes are covered in detail in the Supplementary Informa-
tion.
Many of the genes identi®ed in these `focused' clusters have been
implicated directly or indirectly as cancer biomarkers or mediators
of carcinogenesis. For example, the tumour-suppressor gene PTEN
was downregulated, whereas the proto-oncogene MYC was up-
regulated in our microarray analysis of prostate cancer (see ref. 1
and Supplementary Information). Likewise, we observed decreased
expression of CDH1 (E-cadherin) and increased expression of fatty
acid synthase, both of which have been shown to be dysregulated in
prostate cancer12,13. In addition to uncharacterized expressed
sequence tags (ESTs), numerous genes were identi®ed by our
screen but not previously known to be associated with prostate
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Figure 1 The molecular signature of prostate cancer. Gene-expression pro®les of 44
experimental samples were performed using two distinct normal prostate reference pools
(NAP pool and commercial pool). Samples analysed included NAP, localized (PCA) and
metastatic (MET) prostate cancer, BPH, three prostate-cancer cell lines (DU-145, LnCAP
and PC3) and prostatitis. a, Dendrograms reveal the variation in gene-expression pattern
between experimental samples in the two pools. Asterisk indicates a sample that was
initially documented as BPH, but later con®rmed to have 5% cancer tissue. b, c, Cluster
diagrams of the sample groups compared with the pool of normal adjacent prostate (b) or
of commercial prostate (c). This clustering identi®es distinct patterns of gene expression
among the groups. Each row represents a single gene (1,520 genes in b, and 1,006
genes in c). Data are the quotient of hybridization of the ¯uorescent cDNA probe prepared
from each experimental messenger RNA to its reference pool, and are a measure of
relative gene expression in each sample. Red and green represent up- and
downregulation, respectively (see scale in lower left corner), relative to the median of the
pool. Grey signi®es technically inadequate or missing data (NP, not present). Black bars on
the sides (B1±B6 and C1±C6) indicate regions with characteristic gene expression
signatures. Enlarged sections of B4 and B6 show selected genes. See Supplementary
Information for full data sets.
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Figure 2 Hepsin is overexpressed in prostate cancer. a, Northern blot analysis of human
hepsin and normalization with GAPDH. PCA, localized prostate cancer. b, Tissue
microarrays used for hepsin analysis (stained with haematoxylin and eosin).
c, Representative elements of a tissue microarray stained with anti-hepsin antibody.
Immunohistochemical stains demonstrate absent or weak staining of benign prostate (c1),
and strong staining in localized prostate cancer (c2±6). Magni®cation ´100. d, Benign
prostate glands demonstrate strong basal cell staining (d1, arrows) but weak expression in
the secretory luminal cells (d2, arrows). Where prostate cancer and benign prostate
glands are seen (d2), marked differences in hepsin staining are observed. In®ltrating
prostate cancers (d3 and d4) demonstrate strong expression of hepsin. Magni®cation
´400. e, Histogram of hepsin expression by tissue type. The relative strength of hepsin
staining was assessed qualitatively (see text). HR-PCA, hormone refractory prostate
cancer. f, Kaplan±Meier analysis. PSA-free survival was strati®ed by level of hepsin











































Figure 3 PIM1 is overexpressed in prostate cancer. a, Representative elements of a tissue
microarray stained with anti-PIM1 antibody. Staining is absent or weak in benign prostate
(top), but strong in the cytoplasm of localized prostate cancer (bottom). Magni®cation
´200. b, PIM1 expression is absent or weak in the secretory luminal cells of benign
prostate glands (top), but strong in in®ltrating prostate cancers (bottom). Magni®cation
´1,000. c, PIM1 protein expression by tissue type as assessed from 810 tissue-
microarray elements. d, Kaplan±Meier analysis shows that patients with prostate cancer
that have negative or weak PIM1 expression (red) are at a greater risk of developing PSA
failure after prostatectomy than those that have moderate or strong expression (blue)
(log-rank test, P = 0.04).
© 2001 Macmillan Magazines Ltd
letters to nature
NATURE | VOL 412 | 23 AUGUST 2001 | www.nature.com 825
groups of known, named genes (see Supplementary Information).
Selected genes identi®ed by microarray analysis were corrobo-
rated by northern analysis. For example, hevin, four and a half LIM
domain protein and gelsolin were shown to be 3.2-, 3.2- and 1.9-
fold downregulated, respectively, by microarray and 8.8-, 4.5- and
3.5-fold downregulated by northern analysis (data not shown).
Similarly, hepsin was 4.3-fold upregulated by microarray and 11.3-
fold upregulated by northern analysis (Fig. 2a). As hepsin is a cell-
surface serine protease with transcript expression precisely
restricted to localized and metastatic prostate cancer, we chose to
examine its expression in more detail at the protein level.
We used a method for evaluating tumour tissues in large numbers
on a single glass slide14. Sections of the microarrays of prostate-
cancer tissue15 used in this study are shown stained with haematoxy-
lin and eosin in Fig. 2b. Hepsin immunohistochemistry was
performed on three tissue microarrays containing a total of 738
specimens (Fig. 2c±e) using an af®nity-puri®ed hepsin-peptide
antibody16. These samples included benign prostate tissue, BPH,
high-grade prostatic intra-epithelial neoplasia (HG-PIN), and
localized and metastatic prostate-cancer samples. Overall, hepsin
exhibited staining predominantly in the plasma membrane and was
preferentially expressed in neoplastic prostate over benign prostate
(Mann±Whitney U-test, P , 0.0001). Importantly, the precursor
lesion of prostate cancer, HG-PIN, had the strongest expression of
hepsin, and almost never lacked staining (Mann±Whitney U-test,
P , 0.0001). Most cases of low or absent hepsin staining were seen
in benign prostate specimens (Fig. 2e). Interestingly, hormone-
refractory metastatic cancers were intermediate in staining
intensity between localized prostate tumours and benign prostate.
Men who develop elevated PSA levels following radical prosta-
tectomy are at a high risk to develop distant metastases and die
because of prostate cancer (termed PSA failure)17. Therefore to
assess the usefulness of hepsin as a potential prostate-cancer
biomarker, PSA failure was de®ned as a PSA elevation of greater
than 0.2 ng ml-1 following radical prostatectomy. Outcomes analy-
sis was performed on like-treated cases, and therefore was restricted
to the 334 prostate-cancer samples from 78 men with clinically
localized prostate cancer (each patient's tumour is replicated on
average four times). The analysis was performed on 334 samples of
localized prostate cancer, treating each as an independent sample.
PSA elevation following radical prostatectomy was signi®cantly
associated with absent or low hepsin immunostaining, (Fig. 2f;
log-rank test, P = 0.03).
Multivariate analysis was performed to examine whether these
results were independent of the Gleason score, a well established
histological grading system for prostate cancer18. Fitting a Cox
proportional hazards model indicates an association of weak or
absent hepsin protein expression in prostate cancer with increased
risk of PSA elevation following prostatectomy, similar to having
a high Gleason score (corresponding hazard ratios (HRs) were 2.9
(P = 0.0004) and 1.65 (P = 0.037), respectively). Weak or absent
hepsin expression was also associated with large prostate cancers:
the median tumour dimension for prostate tumours with moderate
or strong expression was 1.3 cm but 1.5 cm for tumours with absent
or weak staining (Mann±Whitney U-test, P = 0.043). Taken
together, expression of hepsin protein in prostate cancer correlated
inversely with measures of patient prognosis.
It is well known that the oncogene MYC is overexpressed in
prostate cancer1,19; we demonstrate here that the protein kinase
encoded by the proto-oncogene PIM1 is similarly upregulated
(Supplementary Information Fig. 7). Our analysis supports a
remarkably similar co-transcriptional regulation (or gene ampli®-
cation) of PIM1 and MYC, possibly mediating a synergistic onco-
genic effect in prostate cancer. Similar to hepsin, we explored
expression of the protein PIM1 kinase in prostate cancer using
high-density tissue microarrays. No or weak PIM1 expression was
observed in most benign prostatic epithelial (97%), prostatic
atrophy (73%) and HG-PIN (82%) samples (Fig. 3a±c). In contrast,
moderate to strong PIM1 expression was observed in approximately
half of the prostate cancer samples (51%; Fig. 3c). Kaplan±Meier
analysis for PSA-free survival demonstrated that positive extrapro-
static extensions, seminal vesicle invasions, Gleason scores greater
than seven and decreased PIM1 expression were associated with a
higher cumulative rate of PSA failure (Fig. 3d). By univariate Cox
models, PIM1 expression is a strong predictor of PSA recurrence
(HR = 2.1 (95% con®dence interval 1.2±3.8), P = 0.01). Among the
variables examined, signi®cant predictors of PSA recurrence were
Gleason score (HR = 1.8 (1.1±3.0), P = 0.03), Gleason pattern 4/5
prostate cancer (HR = 3.9 (1.8±8.3), P , 0.001), extraprostatic
extension status (HR = 2.6 (1.6±4.2), P , 0.0001), surgical
margin status (HR = 2.6 (1.2±5.6), P = 0.01), seminal vesicle
status (HR = 3.5 (2.0±6.2), P , 0.0001), the natural log of pre-
operative PSA level (HR = 2.5 (1.6±3.8), P , 0.001), and maximum
tumour dimension (HR = 2.7 (1.6±4.7), P , 0.0001). By a multi-
variate Cox model, signi®cant predictors of PSA recurrence were
the presence of Gleason grades 4 and 5 prostate cancer (HR = 3.8
(1.4±10.0), P , 0.01), the natural log of pre-operative PSA level
(HR = 2.1 (1.1±3.9), P = 0.02), and decreased PIM1 expression (HR
= 4.5 (1.6±15.2), P = 0.01). Thus, even more so than hepsin,
decreased expression of PIM1 kinase in prostate cancer correlated
signi®cantly with measures of poor patient outcome.
Analysis of the differential gene-expression pro®les of normal and
neoplastic prostate has identi®ed a select set of genes that de®ne a
molecular signature for prostate cancer. By making direct compara-
tive hybridizations of normal and neoplastic tissues, we emphasized
genes that molecularly distinguish benign tissue from malignantÐ
possibly accounting for the abundance of cancer-related genes
picked up by our screen. Combining tissue microarrays, cDNA
microarrays, and linked clinical and pathology data will facilitate
rapid characterization of candidate biomarkers and regulatory
cancer genes, as demonstrated here with respect to hepsin and
PIM1 kinase. M
Methods
Preparation of total RNA and reference pools
The prostate surgical specimens were obtained from The University of Michigan
Specialized Research Program in Prostate Cancer (SPORE) tumour bank with Institu-
tional Review Board approval. Tissues were homogenized in Trizol (Gibco) and the total
RNA was isolated according to the standard Trizol protocol. Total RNA integrity was
judged by denaturing-formaldehyde agarose gel electrophoresis. Total RNA from four
normal tissues was combined in equal concentrations to obtain the reference pool. The
human prostate total RNA used in the commercial reference pool was obtained from
Clontech.
Microarray procedures
Complementary DNA microarray analysis of gene expression was done essentially as
described (available at http://www.microarrays.org). The sequence-veri®ed cDNA clones
on the human cDNA microarray are listed in the Supplementary Information and are
available from the Research Genetics web site (http://www.resgen.com). Based on the
latest build of Unigene, our 10K human cDNA micorarray covers about 5,520 known,
named genes and 4,464 ESTs. Protocols for printing and post-processing of arrays are
available (http://www.microarrays.org/protocols.html).
Data analysis
Primary analysis was done with the Genepix software package. Cy3-to-Cy5 ratios are
determined for the individual genes along with various other quality-control parameters
(for example, intensity over local background). Furthermore, bad spots or areas of the
array with obvious defects were manually ¯agged. Flagged spots were not included in
subsequent analyses.
These ®les were then imported into a Microsoft Access database. Before clustering, the
normalized median of ratio values of the genes were log2 transformed, ®ltered for presence
across arrays, and selected for expression levels and patterns depending on the experi-
mental set as stated in the ®gure legends. Average-linkage hierarchial clustering of an
uncentred Pearson correlation similarity matrix was applied with the program Cluster11,
and the results were analysed; ®gures were generated with the program TreeView. Before
hierarchical clustering, the data were ®ltered for at least a twofold change in expression
ratio and ratio measurements present in 50% of the samples, thus yielding 1,520 genes
from the NAP data set (Fig. 1b). Similarly, a threefold change with 75% measurements
present yielded 1,006 genes from the commercial pool (Fig. 1c) data set.
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Northern blot analysis
Thirty micrograms of total RNA were resolved by denaturing-formaldehyde agarose gel
and transferred onto Hybond membrane (Amersham). The signal was visualized and
quanti®ed by phosphorimaging. For relative fold estimation, the ratio between the signals
obtained from hepsin and GAPDH probes was calculated. For northern analysis, we
compared the intensity of the transcript (as determined by phosphorimaging) in NAP
tissue with that of localized prostate cancer. The results are ®rst normalized against a
GAPDH control and a ratio of cancer to normal is then obtained. Similarly, for microarray
analysis, the normalized Cy5/Cy3 quotient of normal tissue is compared to the Cy5/Cy3
quotient of prostate cancer and a ratio of cancer to normal tissue is obtained.
Immunohistochemistry and tissue microarrays
High-density tissue microarrays were assembled as previously described14,15. Initial
sections were stained for haematoxylin and eosin to verify histology. Standard biotin±
avidin-complex immunohistochemistry was performed. The af®nity-puri®ed polyclonal
rabbit antibody against hepsin was used at a 1:40 dilution (original concentration
0.2 mg ml-1) for this study. Immunostaining intensity was scored by a genito-urinary
pathologist (M.A.R.) as absent, weak, moderate or strong. Scoring was performed blind
using a telepathology system without knowledge of overall Gleason score (for example,
tumour grade), tumour size or clinical outcome15. A total of 738 tissue samples from
benign (n = 205), HG-PIN (n = 38), localized prostate cancer (n = 335) and metastatic
prostate cancer (n = 160) were examined.
Similarly, PIM1 was analysed using two tissue-microarray blocks from 810 prostate-
cancer samples from 135 patients. Six prostate-cancer samples were evaluated from each
case and a median score was calculated. In addition, a few samples with benign prostatic
tissues (for example, benign epithelium and atrophy) and HG-PIN were examined.
Immunohistochemistry was performed as above, using a rabbit polyclonal antibody
against the carboxy terminus of PIM1 (Santa Cruz Biotechnology) at a dilution of
1:100.
Case selection
Cases of clinically localized prostate cancer were identi®ed from the University of
Michigan Prostate SPORE tumour bank. The advanced prostate tumours were collected
from a series of rapid autopsies performed at the University of Michigan on men who died
of metastatic prostate cancer. Autopsies were performed 4±6 h after death. The clinical and
pathologic ®ndings of these cases have recently been reported20.
Statistical methods
A nonparametric analysis of variance test (Mann±Whitney, two categories) was used to
evaluate whether the prostate samples expressed hepsin and PIM1 at different levels based
on various parameters (tissue type, Gleason score and tumour size). Kaplan±Meier
analysis was used to estimate the cumulative percentage of PSA-free progression
(`survival'). The log-rank test was used to assess the differences in disease-free progression
hepsin immunostaining. Cox proportional-hazard regression was used for multivariate
analyses.
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Cell migration is a fundamental biological process involving
membrane polarization and cytoskeletal dynamics1, both of
which are regulated by Rho family GTPases2±5. Among these
molecules, Rac is crucial for generating the actin-rich lamelli-
podial protrusion, a principal part of the driving force for
movement3,6. The CDM family proteins, Caenorhabditis elegans
CED-5, human DOCK180 and Drosophila melanogaster Myoblast
City (MBC), are implicated to mediate membrane extension by
functioning upstream of Rac7±12. Although genetic analysis has
shown that CED-5 and Myoblast City are crucial for migration of
particular types of cells8,9,12, physiological relevance of the CDM
family proteins in mammals remains unknown. Here we show
that DOCK2, a haematopoietic cell-speci®c CDM family protein13,
is indispensable for lymphocyte chemotaxis. DOCK2-de®cient
mice (DOCK2-/-) exhibited migration defects of T and B lympho-
cytes, but not of monocytes, in response to chemokines, resulting
in several abnormalities including T lymphocytopenia, atrophy of
lymphoid follicles and loss of marginal-zone B cells. In DOCK2-/-
lymphocytes, chemokine-induced Rac activation and actin poly-
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